Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | PRCP | P42785 | 3/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733386 | 1.00 | NAAA (0.56) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12733395 | 1.00 | NAAA (0.56) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL17817483 | 1.00 | NAAA (0.56) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12733388 | 0.98 | NPSR1 (0.54) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL10304470 | 0.95 | NAAA (0.59) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12733387 | 0.94 | NPSR1 (0.59) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL21696640 | 0.94 | NPSR1 (0.59) | NAAANPSR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12733389 | 0.87 | NPSR1 (0.48) | NAAANPSR1FKBP1AEPHX1KDM4E | |
| SCHEMBL26343602 | 0.87 | NPSR1 (0.48) | NAAANPSR1FKBP1AEPHX1KDM4E | |
| SCHEMBL5100899 | 0.83 | NPSR1 (0.45) | NPSR1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | NAAA 2554/4885NPSR1 877/4885GNAI3 3704/4885 |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | BCL2A1, CSTB, BAK1 | NAAA 3051/4885NPSR1 759/4885GNAI3 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.